CONTEXT AND OBJECTIVE: Prostate cancer (PCa) is the second most common cancer among men in Brazil. Recently, several studies have hypothesized a relationship between PCa and metabolic syndrome (MS). The aim here was to identify an association between MS and PCa. DESIGN AND SETTING:Cross-sectional study, Fundação de Benefi cência Hospital de Cirurgia (FBHC) and Universidade Federal de Sergipe. METHODS:Laboratory and anthropometric parameters were compared between PCa patients (n = 16) and controls (n = 16). RESULTS:The PCa patients showed signifi cantly greater frequency of MS than did the controls (p = 0.034). Serum glucose was higher and high-density lipoprotein-cholesterol was lower than in the controls, although without signifi cant differences. There were signifi cant differences in blood pressure (p = 0.029) and waist-to-hip ratio (p = 0.004). Pearson linear correlation showed a positive association between waist-to-hip ratio and prostate specifi c antigen (r = 0.584 and p = 0.028). Comparing subgroups with and without MS among the PCa patients, signifi cant differences (p < 0.05) in weight, height, body mass index, hip circumference and lean body mass were observed, thus showing higher central obesity in those with MS. The serum glucose values were also higher in MS patients (p = 0.006), thus demonstrating that insulin resistance has a role in MS physiopathology. CONCLUSIONS:Our study suggests that MS may exert an infl uence on the development of PCa. However, it would be necessary to expand the investigation fi eld with larger sample sizes and cohorts studied, to test the hypothesis generated in this study.

e19628 Background: Fatigue is one of the most frequent symptoms in cancer patients, characterized by profound fatigue that is not relieved by rest. This symptom can be identified at the time of diagnosis and could affects up to 90% of patients undergoing cancer treatment. There are some instruments available in the literature that can characterize the presence of fatigue through clinical questioning. Methods: Considering the large population of patients with metastatic colorectal cancer treated with chemotherapy and the prevalence of fatigue in these patients, this study evaluated the presence of fatigue in 27 metastatic colon cancer patients before the first, second, third and fourth cycles of fist line palliative chemotherapy regimen containing CAPOX (capecitabine and oxaliplatin) by applying the evaluation questionnaire FACIT-F fatigue. Results: The results post Friedman chi-squared test demonstrated that there was no improvement of fatigue during these four cycles of CAPOX palliative chemotherapy (p=0,2574). The FACIT-G analysis demonstrated no worsening of quality of life (p=0,2411) during and between the four cycles of chemo. All different parameters included in FACIT-F questionnaires: emotional (p=0,2629), physical (p=0,3199), familiar (p=0,1456), functional (p=0,8662) and specific fatigue topic (p=0,7569) confirmed no difference between the cycles. Conclusions: Despite the metastatic stage of colon cancer patients and concurrent chemotherapy treatment, there was no fatigue improvement during the four first CAPOX chemo cycles courses and there was the maintenance of quality of life.

Pemetrexed is a novel, multitargeted antifolate approved for the treatment of malignant pleural mesothelioma and non-small cell lung cancer. Although pemetrexed is a safe drug, some adverse effects such as myelosupression and cutaneous reactions are observed. Pemetrexed-induced eyelid edema is a rare side effect of pemetrexed treatment, and until this moment few cases were reported in the medical literature. We reported a new case of pemetrexed-induced eyelid edema in a patient with adenocarcinoma of the lung with brain metastases.

No abstract

The differential diagnosis, treatment and prognosis of pancreatic ductal adenocarcinoma (PA) are still a challenge in clinical practice. The aim of the current study was to assess the role of select plasma and tissue microRNAs (miRs‐21, ‐23a, ‐100, ‐107, ‐181c e ‐210) as biomarkers for the diagnosis of PDCA. Samples of plasma (PAp Group, n=13), pancreatic tumors (PAt Group, n=18) and peritumoral regions (PPT Group, n=9) were collected from patients during the surgical procedure. The control group consisted of samples collected from patients submitted to pancreatic surgery for trauma or from cadaveric organ donors (PC Group, n=7). Healthy volunteers donated blood for plasma collection (PCp Group, n=6). The relative abundance of six miRNAs was measured in all groups using real‐time PCR, and serum CA 19‐9 levels were determined in Groups PA and PC, with the difference being considered significant when p <0.05. In tissue samples, there was a difference in the expression of miRNA‐21 (p=0.005) and miRNA‐210 (p=0.008) across the PAt, PC and PPT groups; miRNA‐21 distinguished group PAt from PC and PPT and miRNA‐210 distinguished group PAt from PC. Serum CA 19‐9 showed 88% accuracy (ROC‐AUC 0.95; 0.84 – 1), 83% sensitivity, and 100% specificity at a cut‐off of 37 ng/dl. The PAp group showed overexpression of miR‐181c (95% CI1.67 – 17.68; p<0.00001) and miR‐210 (95% CI0.16 – 5,20; p=0.03) compared to the PCp group. The combination of tissue expression of miR‐21, ‐210 and serum CA 19‐9 showed 100% accuracy for the diagnosis of PA, and the accuracy of plasma miR‐181c (PAp × PCp) was also 100%. These findings suggest that the combination of tissue miRNAs and serum CA 19‐9 can improve accuracy, but plasma miRNA expression can be used as a noninvasive diagnostic test for PA, although further studies are necessary to validate these results as well as to evaluate the utility of miRNA expression as a biomarker related to survival and to the response to therapy in PA.This abstract is from the Experimental Biology 2018 Meeting. There is no full text article associated with this abstract published in The FASEB Journal.